Giredestrant CAS 1953133-47-5 MF C27H31F5N4O MW 522.6 g/mol 3-[(1R,3R)-1-[2,6-difluoro-4-[[1-(3-fluoropropyl)azetidin-3-yl]amino]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2,2-difluoropropan-1-ol 3-((1R,3R)-1-(2,6-Difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol (1R,3R)-1-[2,6-Difluoro-4-[[1-(3-fluoropropyl)-3-azetidinyl]amino]phenyl]-beta,beta-difluoro-1,3,4,9-tetrahydro-3-methyl-2H-pyrido[3,4-b]indole-2-propanol Wilserdly, FDA 2026, APPROVALS 2026, GDC 9545, RG 6171, RO 7197597, 28P3DU6DB3 To treat adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, estrogen receptor 1-mutated locally advanced or metastatic breast cancer whose disease has recurred during or after endocrine-based adjuvant therapy, or … Continue reading Giredestrant
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed